Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in China: Current immunization strategy effectively prevented its sustained transmission

Journal of Infectious Diseases

Volumn 202, Issue 12, 2010, Pages 1780-1788

  Zhang, Yong ^a   Yan, Dongmei ^a   Zhu, Shuangli ^a   Wen, Ning ^a   Li, Li ^a   Wang, Haiyan ^b   Liu, Jianfeng ^c   Ye, Xufang ^d   Ding, Zhengrong ^e   Wang, Dongyan ^a   Zhu, Hui ^a   Chen, Li ^a   Hou, Xiaohui ^a   An, Hongqiu ^a   Liang, Xiaofeng ^a   Luo, Huiming ^a   Kew, Olen ^f   Xu, Wenbo ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SHANDONG CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Gansu Center for Disease Control and Prevention   (China)

^d Guizhou Center for Disease Control and Prevention   (China)

^e YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ARTICLE; CHILD; CHINA; CLINICAL ARTICLE; FEMALE; FLACCID PARALYSIS; HUMAN; IMMUNIZATION; INFANT; MALE; NUCLEOTIDE SEQUENCE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSMISSION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHINA; CLUSTER ANALYSIS; FEMALE; HUMANS; IMMUNIZATION; INFANT; MALE; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; PHYLOGENY; POINT MUTATION; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY;

EID: 78650347029     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/657410     Document Type: Article

References (46)

1. Wang K, Zhang LB, Otten MW Jr, et al. Status of the eradication of indigenous wild poliomyelitis in the People's Republic of China. J Infect Dis 1997; 175(suppl 1):S105-S112.
2. Centers for Disease Control and Prevention. Certification of poliomyelitis eradication-Western Pacific Region, October 2000. MMWR Morb Mortal Wkly Rep 2001; 50:1-3.
3. Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull World Health Organ 2004; 82:16-23.
4. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59:587-635.
5. Zhang J, Zhang LB, Otten MW Jr, et al. Surveillance for polio eradication in the People's Republic of China. J Infect Dis 1997; 175(suppl 1):S122-S134.
6. Centers for Disease Control and Prevention (CDC). National poliomyelitis immunization days-People's Republic of China, 1993.MMWR Morb Mortal Wkly Rep 1993; 42:837-839.
7. Freistadt MS, Vaccaro JA, Eberle KE. Biochemical characterization of the fidelity of poliovirus RNA-dependent RNA polymerase. Virol J 2007; 4:44.
8. Dahourou G, Guillot S, Le Gall O, Crainic R. Genetic recombination in wild-type poliovirus. J Gen Virol 2002; 83:3103-3110.
9. de la Torre JC, Giachetti C, Semler BL, Holland JJ. High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus. Proc Natl Acad Sci U S A 1992; 89: 2531-2535.
10. Kew OM, Nottay BK, Hatch MH, Nakano JH, Obijeski JF. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. J Gen Virol 1981; 56:337-347.
11. Nomoto A, Omata T, Toyoda H, et al. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A 1982; 79:5793-5977.
12. Georgescu MM, Delpeyroux F, Tardy-Panit M, et al. High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis. J Virol 1994; 68: 8089-8101.
13. Yang CF, Naguib T, Yang SJ, et al. Circulation of endemic type 2 vaccinederived poliovirus in Egypt from 1983 to 1993. J Virol 2003; 77: 8366-8377.
14. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296:356-359.
15. Shimizu H, Thorley B, Paladin FJ, et al. Circulation of type 1 vaccinederived poliovirus in the Philippines in 2001. J Virol 2004; 78: 13512-13521.
16. Rakoto-Andrianarivelo M, Gumede N, Jegouic S, et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J Infect Dis 2008; 197:1427-1435.
17. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine-derived poliovirus in Madagascar. Emerg Infect Dis 2003; 9:885-887.
18. Liang X, Zhang Y, Xu W, et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. J Infect Dis 2006; 194: 545-551.
19. Estivariz CF, Watkins MA, Handoko D, et al. A large vaccine-derived poliovirus outbreak on Madura Island-Indonesia, 2005. J Infect Dis 2008; 197:347-354.
20. Wringe A, Fine PE, Sutter RW, Kew OM. Estimating the extent of vaccine-derived poliovirus infection. PLoS One 2008; 3:e3433.
21. World Health Organization. Global update on vaccine-derived polioviruses, January 2006-August 2007. Wkly Epidemiol Rec 2007; 82: 337-343.
22. Martin J. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 2006; 34:117-122.
23. World Health Organization. Vaccine-derived polioviruses-update. Wkly Epidemiol Rec 2006; 81:398-404.
24. Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999; 150:1001-1021.
25. Friedrich F, Da-Silva EF, Schatzmayr HG. Type 2 poliovirus recombinants isolated from vaccine-associated cases and from healthy contacts in Brazil. Acta Virol 1996; 40:27-33. (Pubitemid 26169804)
26. Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses-worldwide, January 2006-August 2007. MMWR Morb Mortal Wkly Rep 2007; 56:996-1001.
27. World Health Organization (WHO). Polio laboratory manual. 4th ed. WHO publication no. WHO/IVB/04.10. Geneva, Switzerland: WHO, 2004.
28. Balanant J, Guillot S, Candrea A, Delpeyroux F, Crainic R. The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay. Virology 1991; 184:645-654.
29. van der Avoort HG, Hull BP, Hovi T, et al. Comparative study of five methods for intratypic differentiation of polioviruses. J Clin Microbiol 1995; 33:2562-2566.
30. Zhang Y, Zhang F, Zhu S, et al. A Sabin 2-related poliovirus recombinant contains a homologous sequence of human enterovirus species C in the viral polymerase coding region. Arch Virol 2010; 155:197-205.
31. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-1599.
32. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160.
33. Galtier N, Gouy M, Gautier C. SEAVIEW and PHYLO-WIN: two graphic tools for sequence alignment and molecular phylogeny. Comput Appl Biosci 1996; 12:543-548.
34. Page RD. TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 1996; 12:357-358.
35. Jorba J, Campagnoli R, De L, Kew O. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J Virol 2008; 82:4429-4440.
36. Zhang Y, Wang H, Zhu S, et al. Characterization of a rare natural intertypic type 2/type 3 penta-recombinant vaccine-derived poliovirus isolated from a child with acute flaccid paralysis. J Gen Virol 2010; 91:421-429.
37. Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 1993; 192:18-26.
38. Minor PD, Macadam AJ, Stone DM, Almond JW. Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 1993; 21: 357-363.
39. Ren RB, Moss EG, Racaniello VR. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol 1991; 65: 1377-1382.
40. Minor PD. Antigenic structure of picornaviruses. Curr Top Microbiol Immunol 1990; 161:121-154.
41. Progress toward interruption of wild poliovirus transmission-worldwide, January 2007-April 2008. MMWRMorb Mortal Wkly Rep 2008; 57:489-494.
42. Expanded programme on immunization (EPI): progress towards poliomyelitis eradication, 1990-1996. Wkly Epidemiol Rec 1996; 71: 377-379.
43. Centers for Disease Control and Prevention. Importation of wild poliovirus into Qinghai Province-China, 1999. MMWR Morb Mortal Wkly Rep 2000; 49:113-114.
44. Kew OM, Sutter RW, Nottay BK, et al. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J Clin Microbiol 1998; 36:2893-2899.
45. Liu HM, Zheng DP, Zhang LB, Oberste MS, Pallansch MA, Kew OM. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J Virol 2000; 74:11153-11161.
46. Lakhiani CN, Vivier PM, Alario AJ, Simon P, Diana BJ, Peter G. Analysis of the transition from oral polio vaccine to inactivated polio vaccine for primary immunization in a hospital-based primary care practice. Pediatr Infect Dis J 2000; 19:575-576.